Administration of Topical Ophthalmic Medication (ATOM): Feasibility of the spraynozzle technique.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28128

Enrollment

Registered

2012-04-23

Start date

2012-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ophthalmic drug dispersal.

Interventions

Topical ocular administration of fluorescein by two different methods. 1. Conventional eye drops in one eye

2. ADE Fluorescein A in fellow eye.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent; 2. Age > 18 years.

Exclusion criteria

Exclusion criteria: 1. Allergy/hypersensitivity for fluorescein; 2. Previous ocular surgery, including refractive laser surgery; 3. Corneal condition (e.g. Sjögren, punctata); 4. Contact lens wear; 5. Concurrent use of eye drops; 6. Active epithelial HSV keratitis; 7. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Autofluorescence of the cornea, anterior chamber, vitreous and retina.	—

Secondary

Measure	Time frame
1. Treatment satisfaction score (TSS); 2. Blinking reflex (qualitative assessment by investigator).	—

Contacts

Public ContactJ. Rooij, van

The Rotterdam Eye Hospital PO Box 70030

+31 (0)10 4017777

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)